Cancer and thromboembolic disease: pathogenic mechanisms

Green, 1996, Hypercoagulability in cancer, Hematol./Oncol. Clin. North America, 10, 499, 10.1016/S0889-8588(05)70349-X Rickles, 2001, Molecular basis for the relationship between thrombosis and cancer, Thromb. Res., 102, V215, 10.1016/S0049-3848(01)00285-7 Hejna, 1999, Inhibition of metastases by anticoagulants, J. Natl. Cancer Inst., 91, 22, 10.1093/jnci/91.1.22 Gale, 2001, Update on tumor cell procoagulant factors, Acta Haematol., 106, 25, 10.1159/000046586 Korte, 2000, Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures, Clin. Chem. Lab. Med., 38, 679, 10.1515/CCLM.2000.099 Falanga, 1998, Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells, Blood, 92, 143, 10.1182/blood.V92.1.143.413k18_143_151 Bauer, 1989, Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans, Blood, 74, 165, 10.1182/blood.V74.1.165.165 Whitehead, 1990, A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study, J. Biol. Response Mod., 9, 588 Lee, 1999, The thrombophilic state induced by therapeutic agents in the cancer patient, Semin. Thromb. Hemost., 25, 137, 10.1055/s-2007-994915 Hallahan, 1999, Drug-radiation interactions in tumor blood vessels, Oncology (Huntingt), 13, 71 Bona, 1999, Thrombotic complications of central venous catheters in cancer patients, Semin. Thromb. Hemost., 25, 147, 10.1055/s-2007-994916